Table 1.
Characteristics of the study subjects.
| Characteristics | PD group (n = 69) | HC group (n = 81) | P value (PD, HC) | SP group (n = 66) | NG Group (n = 97) | P value (PD, NG) |
|---|---|---|---|---|---|---|
| Age (years) | 58.1 (12.0) | 36.3 (11.2) | <0.001 | 59.0 (12.1) | 65.7(9.3) | 0.608 |
| Female (n, %) | 28 (40.6) | 14 (17.3) | <0.01 | 41 (62.1) | 53 (54.6) | 0.103 |
| BMI (kg/m2) | 23.1 (2.91) | 23.3 (2.5) | 0.919 | 23.2 (3.3) | – | – |
| H&Y stage | 2.2 (0.55) | – | – | – | – | – |
| Age of onset (years) | 58.8 (7.3) | – | – | – | – | – |
| Disease duration (years) | 6.2 (4.5) | – | – | – | – | – |
| MDS_UPDRS | 53.3 (27.0) | – | – | – | – | – |
| MDS_UPDRS_P1 | 8.0 (5.2) | – | – | – | – | – |
| MDS_UPDRS_P2 | 11.1 (7.2) | – | – | – | – | – |
| MDS_UPDRS_P3 | 29.0 (16.5) | – | – | – | – | – |
| MDS_UPDRS_P4 | 2.2 (3.2) | – | – | – | – | – |
| HAMA | 10.1 (6.8) | – | – | – | – | – |
| HAMD | 7.1 (5.2) | – | – | – | – | – |
| MoCA | 23.7 (3.7) | – | – | – | – | – |
| NMSS | 40.1 (26.2) | – | – | – | – | – |
| MMSE | 27.7 (2.7) | – | – | – | – | – |
| WBC | 6.3 (2.3) | – | – | – | – | – |
| NEUT.1 | 62.3 (12.6) | – | – | – | – | – |
| LYM | 26.9 (10.6) | – | – | – | – | – |
| MONO.1 | 7.1 (2.7) | – | – | – | – | – |
| EOSIN | 3.3 (5.3) | – | – | – | – | – |
| BASO | 0.4 (0.3) | – | – | – | – | – |
| NEUT | 4.1 (2.3) | – | – | – | – | – |
| LYM | 1.6 (0.6) | – | – | – | – | – |
| MONO | 0.4 (0.2) | – | – | – | – | – |
| EOSIN_COUNT | 0.2 (0.4) | – | – | – | – | – |
| BASO | 0.0 (0.0) | – | – | – | – | – |
| RBC | 4.5 (0.5) | – | – | – | – | – |
| Hb | 133.1 (11.2) | – | – | – | – | – |
| HCT | 40.1 (3.2) | – | – | – | – | – |
| MCV | 90.1(6.4) | – | – | – | – | – |
| MCH | 29.9 (2.2) | – | – | – | – | – |
| MCHC | 331.6 (8.8) | – | – | – | – | – |
| RDW | 12.8 (0.7) | – | – | – | – | – |
| PLT | 215.1 (56.6) | – | – | – | – | – |
| MPV | 9.6 (1.2) | – | – | – | – | – |
| PCT | 0.2 (0.0) | – | – | – | – | – |
| PDW | 12.7 (2.6) | – | – | – | – | – |
PD, Parkinson’s disease; HC, healthy control; SP, spouse of PD patients; NG, normal group; BMI, body mass index; H&Y stage, Hoehn and Yahr stage; MDS-UPDRS, MDS-Unified Parkinson’s Disease Rating Scale; MDS-UPDRS_PI, non-motor experiences of daily living; MDS-UPDRS_P2, motor experiences of daily living; MDS-UPDRS_P3, motor examination; MDS-UPDRS_P4, motor complications; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; MoCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptoms Scale; MMSE, Mini-Mental State Examination; WBC, white blood cell count; NEUT/NEUT.1, neutrophil count/percentage; LYM, lymphocyte; MONO/MONO.1, monocyte count/percentage; EOSIN, eosinophilia; BASO, Basophils; RBC, Red blood cell count; Hb, hemoglobin; HCT, Hematocrit; MCV, Mean red blood cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; RDW, Red blood cell distribution width; PLT, platelet count; MPV, mean platelet volume; PCT, plateletocrit; PDW, platelet distribution width. “-”; not available. Numbers are expressed as mean ± standard deviation. P < 0.05; significant differences; P > 0.05; no differences.